Bryan Garnier - Pernod Ricard (UG) PERNOD RICARD BUY | EUR160 Mixed performance in the EMEA/LATAM region

Report

Bryan Garnier

Virginie Roumage

PERNOD RICARD BUY | EUR160 Mixed performance in the EMEA/LATAM region

PERNOD RICARD BUY | EUR160

Mixed performance in the EMEA/LATAM region

The conference on EMEA/LATAM unveiled contrasted dynamics and goals that depend on the sub-regionâ€¦
Central/Eastern Europe: consolidate the groupâ€™s leadership
LATAM/Africa and Middle East: accelerate growth and gain share
Western Europe: grow Jameson/Absolut
Pernod Ricard should remain active in portfolio management

20/03/2019 3 EN

Underlying

Pernod Ricard

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Virginie Roumage

Other Reports on these Companies

Sabadell

INFORME DIARIO 24 JULIO + RDOS. ESPAÑA Y EUROPA 2T’25. IDEAS DESTACADAS Y PREVIEWS (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACS, BANKINTER, CAF, COLONIAL, IBERDROLA, INDRA, REPSOL, ROVI, VIDRALA. EUROPA: BNP PARIBAS, DEUTSCHE TELEKOM, NOKIA, PERNOD RICARD, UNICREDIT. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 2T’25 que se publicarán en España y Europa en los próximos días. Mayores esperanzas en las negociaciones comerciales Celebración y optimismo en las bolsas europeas, que recuperan lo perdido el día anterior, rebotando ...

EUR 100.00

July 24, 2025 July 24, 2025 1 ES

Sabadell

PERNOD RICARD: RDOS. 1S’25 (ANÁLISIS BANCO SABADELL)

Rdos. 2T'25 vs 2T'24: Ventas: 3.393 M euros (-4,4% vs -0,8% BS(e) y -3,4% consenso); Rdos. 1S'25 vs 1S'24: Ventas: 6.176 M euros (-6,3% vs -4,3% BS(e) y -5,8% consenso); EBIT: 1.985 M euros (-7,4% vs -6,4% BS(e) y -7,8% consenso); BDI: 1.274 M euros (-11,5% vs -9,6% BS(e) y -11,1% consenso).

EUR 100.00

February 6, 2025 February 6, 2025 1 ES

Sabadell

INFORME DIARIO 06 FEBRERO + RDOS. ESPAÑA Y EUROPA 4T’24. PREVIEWS (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ARCELOR MITTAL, CELLNEX, SECTOR AUTOPISTAS, TALGO. EUROPA: AIRBUS, ING GROEP, PERNOD RICARD, SIEMENS, SOCIÉTÉ GÉNÉRALE. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’24 que se publicarán en España y Europa en los próximos días. El Ibex sigue imparable La sesión volvió a estar marcada por los comentarios de D. Trump y su plan sobre Gaza, donde se teme un repunte de la tensión geopolítica además de la...

EUR 100.00

February 6, 2025 February 6, 2025 1 ES

Egetis: Submits pre-NDA meeting, positive recruitment update

Egetis posted a positive US development update on Emcitate with 15 evaluable patients in the US ReTRIACt phase 3 study (vs 12 at previous update) and has submitted a pre-NDA meeting (Type B) request to the FDA, with plans to initiate the submission of the NDA for tiratricol (Emcitate) this year. As

13h / 39m 13h / 39m 1 EN

Damien Choplain ... (+2)

Damien Choplain
Oscar Haffen Lamm

Faron: Positive FDA feedback sends BEX into a registrational phase 2/3 study

Faron is advancing bexmarilimab (BEX) into a registrational phase 2/3 trial in HR-MDS following a positive EOP2 meeting with the FDA. We view the feedback of broadly positive, as the trial design remains largely unchanged, with a single study expected to support approvals in both frontline and rela

13h / 57m 13h / 57m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Fastned: H1 results, GM recovery, roll-out acceleration expected in H2

This morning, Fastned published its H1 2025 key metrics and number of operating stations. H1 sales came in at EUR54.3m (+44% YoY), implying revenue of EUR26.3m in Q2 2025 (-9% vs cons. at EUR28.9m) and pointing to an annual run-rate of at least EUR108m (vs cons. at EUR130.8m for FY25 and STFe EUR13

August 14, 2025 August 14, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

PERNOD RICARD BUY | EUR160 Mixed performance in the EMEA/LATAM region

INFORME DIARIO 24 JULIO + RDOS. ESPAÑA Y EUROPA 2T’25. IDEAS DESTACADAS Y PREVIEWS (ANÁLISIS BANCO SABADELL)

PERNOD RICARD: RDOS. 1S’25 (ANÁLISIS BANCO SABADELL)

INFORME DIARIO 06 FEBRERO + RDOS. ESPAÑA Y EUROPA 4T’24. PREVIEWS (ANÁLISIS BANCO SABADELL)

Egetis: Submits pre-NDA meeting, positive recruitment update

Faron: Positive FDA feedback sends BEX into a registrational phase 2/3 study

Fastned: H1 results, GM recovery, roll-out acceleration expected in H2

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe